¿Cuáles son las características y plataformas tecnológicas de las vacunas covid-19 que llegaron a ensayos clínicos en humanos?
(What are the characteristics and technological platforms of the covid-19 vaccines that reached human clinical trials?)
Primeras 5 respuestas:
-
As clinical trials are ‘rate-limiting’ and ‘time-consuming’, many innovative methods are in practice for a fast track.
-
Vaccine candidates against SARS-CoV-2 are mainly based upon the viral spike protein due to its vital role in viral infectivity,
-
COVID-19 vaccines are most commonly evaluated based on their capability of generating binding and neutralizing antibodies.
-
DNA-and RNA-based platforms present the greatest potential for speed of production since culturing and fermentation are not required for their synthesis.
-
mRNA, DNA, Adenoviral/lentiviral/bacterial vector-based vaccines, and inactivated SARS-CoV-2 [82] .
As clinical trials are ‘rate-limiting’ and ‘time-consuming’, many innovative methods are in practice for a fast track.
... of now, 108 such vaccines are available. Six of these vaccines have entered clinical trials. As clinical trials are ‘rate-limiting’ and ‘time-consuming’, many innovative methods are in practice for a fast track. These include parallel phase I-II trials and obtaining efficacy data from phase IIb trials. Human ...
Ref: COVID-19 vaccines: A race against time in the middle of death and devastation! [J Clin Exp Hepatol, 2020-06-10]Vaccine candidates against SARS-CoV-2 are mainly based upon the viral spike protein due to its vital role in viral infectivity,
... up the establishment of a variety of vaccine platforms. Accordingly, numerous vaccines are under development. Vaccine candidates against SARS-CoV-2 are mainly based upon the viral spike protein due to its vital role in viral infectivity, and most of these candidates have recently moved into clinical trials. Before the efficacy of ...
Ref: Fighting COVID-19: A quick review of diagnoses, therapies, and vaccines [Biomed J, 2020]COVID-19 vaccines are most commonly evaluated based on their capability of generating binding and neutralizing antibodies.
... COVID-19 vaccines are most commonly evaluated based on their capability of generating binding and neutralizing antibodies. However, a range of vaccine evaluation methods and models exist, making it difficult to compare the efficacy of different vaccines. In addition to humoral immunity, specific CD8+ cytotoxic T lymphocytes ...
Ref: Challenges in the development of a vaccine against COVID-19 [Engineering (Beijing), 2020-09-14]DNA-and RNA-based platforms present the greatest potential for speed of production since culturing and fermentation are not required for their synthesis.
... DNA-and RNA-based platforms present the greatest potential for speed of production since culturing and fermentation are not required for their synthesis. The potential of this approach is showcased by Moderna, whose vaccine candidate advanced to clinical testing just 2 months after sequence identification 7 . There are many other advantages associated ...
Ref: Development of vaccines for SARS-CoV-2 [F1000Res, 2020-08-17]mRNA, DNA, Adenoviral/lentiviral/bacterial vector-based vaccines, and inactivated SARS-CoV-2 [82] .
... 2020, 10 candidate vaccines that have made it to clinical stage represent diverse platforms including mRNA, DNA, Adenoviral/lentiviral/bacterial vector-based vaccines, and inactivated SARS-CoV-2 [82] . DNA and mRNA-based platforms offer the advantage of flexibility in terms of antigen manipulation and ...
Ref: Emerging Prevention and Treatment Strategies to Control COVID-19 [Pathogens, 2020-06-23]Bacillus Calmette-Guérin (BCG) vaccines, DNA and RNA-based vaccines, inactivated vaccines, protein subunits, and viral vectors.
... trials worldwide in search for a COVID-19 vaccine. The different vaccine platforms being tested are Bacillus Calmette-Guérin (BCG) vaccines, DNA and RNA-based vaccines, inactivated vaccines, protein subunits, and viral vectors. By thoroughly analyzing different trials and platforms, we also discuss the advantages and disadvantages of ...
Ref: Vaccine Candidates against Coronavirus Infections. Where Does COVID-19 Stand? [Viruses, 2020]Platform technology use systems with the same basic components as a backbone and insert new protein or genetic sequences to adapt for use against different pathogens.
... vaccine programs. 2 Rapid response platforms for vaccine development supported by CEPI are being utilized. Platform technology use systems with the same basic components as a backbone and insert new protein or genetic sequences to adapt for use against different pathogens. 3 The vaccine candidates include a DNA vaccine (administered with electroporation); a molecular-clamp vaccine (synthesis ...
Ref: Planning for COVID-19 Vaccines Safety surveillance [Vaccine, 2020-07-10]These platform technologies range from inactivation and targeted attenuation of live pathogens to the delivery of synthetic peptide antigens and recombinantly produced protein antigens,
... vaccine platform technologies has been developed, thanks to advances primarily in molecular biology and vaccinology. These platform technologies range from inactivation and targeted attenuation of live pathogens to the delivery of synthetic peptide antigens and recombinantly produced protein antigens, as well as viruslike particles (VLPs), non-replicating and replicating viral vectors, polysaccharide-protein conjugates, and nucleic ...
Ref: The Long Road Toward COVID-19 Herd Immunity: Vaccine Platform Technologies and Mass Immunization Strategies [Front Immunol, 2020-07-21]Its biological characteristics, other than receptor binding and membrane fusion, are obscure which may potentially exert other biological activities affecting the vaccine safety and efficacy.
... expressing S protein, however, no other studies supported such claims till date (Roper and Rehm, 2009 ). For COVID-19 vaccine development process S protein is the most targeted candidate antigen. Its biological characteristics, other than receptor binding and membrane fusion, are obscure which may potentially exert other biological activities affecting the vaccine safety and efficacy. ...
Ref: Challenges and prospects of COVID‐19 vaccine development based on the progress made in SARS and MERS vaccine development [Transbound Emerg Dis, 2020-08-20]The vaccine platform functions by synthesizing viral surface proteins that get attached to the host cells and clamp them into shape.
... develop the molecular clamp vaccine platform against multiple viral pathogens including MERS-CoV ($10 M funding). The vaccine platform functions by synthesizing viral surface proteins that get attached to the host cells and clamp them into shape. This facilitates easier recognition of antigens by the immune system. 36 Other than these ongoing ...
Ref: COVID-19, an emerging coronavirus infection: advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics [Hum Vaccin Immunother, 2020-03-18]Future vaccines must ensure the scalability, an adequate price for sustainable investment, and equitable distribution of life-saving vaccines.
... vaccine, multiple products are needed to meet the enormous global demand. Speeding up the development of new vaccines against SARS-CoV-2 is important, but ensuring safety and efficacy in clinical trials. Future vaccines must ensure the scalability, an adequate price for sustainable investment, and equitable distribution of life-saving vaccines. ...
Ref: Vaccine development in the SARS-CoV-2 pandemic: a balancing act on accuracy and speed [Int J Public Health, 2020-10-13]An unprecedented research effort and global coordination has resulted in a rapid development of vaccine candidates and initiation of trials.
... a COVID-19 vaccine is likely the most effective approach to sustainably controlling the COVID-19 pandemic. An unprecedented research effort and global coordination has resulted in a rapid development of vaccine candidates and initiation of trials. Here, we review vaccine types, and progress with 10 vaccine candidates against SARS-CoV-2 - the ...
Ref: Vaccines for COVID-19: The current state of play [Paediatr Respir Rev, 2020]the presented respiratory vaccine candidate is highly attenuated in primates per se, safe and lacking pre-existing immunity in human,
... and this expression did not significantly impact the in vitro growth characteristics of the recombinant Taken together, the presented respiratory vaccine candidate is highly attenuated in primates per se, safe and lacking pre-existing immunity in human, and carries the potential for accelerated vaccine development against CoVID-19 for clinical studies ...
Ref: A Scalable Topical Vectored Vaccine Candidate against SARS-CoV-2 [Vaccines, 2020]DNA, vector based RNA, subunit and many other variants of RNA technologies are undergoing trial in the making of SARS-CoV2 vaccine.
... the history of vaccine development as a successful agent for prevention of Covid-19. Besides this, DNA, vector based RNA, subunit and many other variants of RNA technologies are undergoing trial in the making of SARS-CoV2 vaccine. The concept of messenger RNA vaccine is relatively new but relatively simple in which mRNA ...
Ref: Vaccine Against Covid-19 Disease – Present Status of Development [Indian J Pediatr, 2020-09-03]As vaccine vectors, they offer several advantages including low cost, low resistance to antibiotics, noninvasive administration, and high safety levels.
... As vaccine vectors, they offer several advantages including low cost, low resistance to antibiotics, noninvasive administration, and high safety levels. The most attractive feature is that bifidobacterium tends to elicit high levels of mucosal antibodies against the expressed foreign antigen following uptake via the mucosal immune system [77] . Some ...
Ref: Fighting COVID-19: a quick review of diagnoses, therapies, and vaccines [Biomed J, 2020-05-30]These Phase III trials seek to demonstrate direct benefits of a vaccine on vaccine recipients.
... vaccines, and Phase III clinical trials have begun for 6 novel vaccine candidates to date. These Phase III trials seek to demonstrate direct benefits of a vaccine on vaccine recipients. However, vaccination is also known to bring about indirect benefits to a population through the ...
Ref: Considering indirect benefits is critical when evaluating SARS-CoV-2 vaccine candidates [medRxiv, 2020-08-11]As clinical trials are 'rate-limiting' and 'time-consuming', many innovative methods are in practice for a fast track.
... of now, 108 such vaccines are available. Six of these vaccines have entered clinical trials. As clinical trials are "rate-limiting" and "time-consuming", many innovative methods are in practice for a fast track. These include parallel phase I-II trials and obtaining efficacy data from phase IIb trials. Human ...
Ref: COVID-19 Vaccines: A Race Against Time in the Middle of Death and Devastation! [medRxiv, 2020]Many human viral vaccines are live, attenuated forms of viruses that elicit humoral and cellular immunity.
... syndrome coronavirus (SARS-CoV-2) is urgently needed to stop the spread of this virus among humans. Many human viral vaccines are live, attenuated forms of viruses that elicit humoral and cellular immunity. Here, we describe a cold-adapted live-attenuated vaccine (SARS-CoV-2/human/Korea/CNUHV03-CA22 °C/2020) developed by gradually adapting the growth ...
Ref: Cold-Adapted Live Attenuated SARS-Cov-2 Vaccine Completely Protects Human ACE2 Transgenic Mice from SARS-Cov-2 Infection. [Vaccines, 2020-10-03]Both SARS-CoV and SARS-CoV-2 has a high degree of genetic similarity and bind to the same host cell ACE2 receptor.
... have opened the door for the scientist to design a new vaccine for the COVID-19. Both SARS-CoV and SARS-CoV-2 has a high degree of genetic similarity and bind to the same host cell ACE2 receptor. By using different vaccine development platforms including whole virus vaccines, recombinant protein subunit vaccines, and ...
Ref: A review on Promising vaccine development progress for COVID-19 disease [Vacunas (Madrid), 2020]Our predicted vaccine targets have the potential for effective and safe COVID-19 vaccine development.
... predicted linear B-cell epitopes were found to be localized on the surface of the protein. Our predicted vaccine targets have the potential for effective and safe COVID-19 vaccine development. We also propose that an "Sp/Nsp cocktail vaccine" containing a structural protein(s) (Sp) and a ...
Ref: COVID-19 Coronavirus Vaccine Design Using Reverse Vaccinology and Machine Learning [Front Immunol, 2020]To mitigate the public health, economic and societal impacts of the virus, a vaccine is urgently needed.
... (SARS-CoV-2) emerged in late 2019 in China and caused a coronavirus disease 2019 (COVID-19) pandemic. To mitigate the public health, economic and societal impacts of the virus, a vaccine is urgently needed. The development of SARS-CoV-2 vaccines was initiated in early January 2020 when the sequence of ...
Ref: SARS-CoV-2 vaccines in development. [Nature, 2020-09-23]These are the fastest in development and do not require fermentation or culture.
... These are the fastest in development and do not require fermentation or culture. Nucleic acid-based vaccines are obtained by inserting mRNA and DNA acids into some cells of vaccinated individuals, forcing them to manufacture immunogenic viral proteins [41] . During pandemics, the use ...
Ref: Recent advances, approaches and challenges in targeting pathways for potential COVID-19 vaccines development [Immunol Res, 2020-10-01]BBIBP-CorV exhibits efficient productivity and good genetic stability for vaccine manufacture.
... highly efficient protection against SARS-CoV-2 intratracheal challenge in rhesus macaques, without detectable antibody-dependent enhancement of infection. In addition, BBIBP-CorV exhibits efficient productivity and good genetic stability for vaccine manufacture. These results support the further evaluation of BBIBP-CorV in a clinical trial. ...
Ref: Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2 [Cell, 2020]antigen selection and engineering, preclinical challenge studies in non-human primate models, and immune correlates of protection.
... Multiple SARS-CoV-2 vaccine candidates have been evaluated in preclinical models and are currently in clinical trials. In this Perspective, we discuss three topics that are critical for SARS-CoV-2 vaccine development: antigen selection and engineering, preclinical challenge studies in non-human primate models, and immune correlates of protection. ...
Ref: Approaches and Challenges in SARS-CoV-2 Vaccine Development [Cell, 2020]Factors from essential features of safety, efficacy, manufacturing, and distributions to administration approaches are taken into consideration based on advances in materials science and engineering technologies.
... pushed into clinical trials simultaneously, and manufacturing capability must be scaled up in early stages. Factors from essential features of safety, efficacy, manufacturing, and distributions to administration approaches are taken into consideration based on advances in materials science and engineering technologies. In this review, we present recent advances in vaccine development by focusing on vaccine discovery, ...
Ref: Engineering Antiviral Vaccines [ACS nano, 2020]using new pathways to facilitate its large-scale development, testing, and manufacture.
... in structural and genomic biology that facilitates the urgent development of an ideal COVID-19 vaccine, using new pathways to facilitate its large-scale development, testing, and manufacture. Here, we summarize the types of COVID-19 candidate vaccines, their current stage in early testing ...
Ref: Recent advances, approaches and challenges in targeting pathways for potential COVID-19 vaccines development [Immunol. res, 2020]Most of the efforts for developing CoV vaccines and drugs target the spike glycoprotein or S protein, the major inducer of neutralizing antibodies.
... decades. However, to date, no licensed antiviral treatment or vaccine exists for MERS and SARS. Most of the efforts for developing CoV vaccines and drugs target the spike glycoprotein or S protein, the major inducer of neutralizing antibodies. Although a few candidates have shown efficacy in in vitro studies, not many have progressed ...
Ref: COVID-19, an emerging coronavirus infection: advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics [Hum Vaccin Immunother, 2020]For vaccines based on novel technologies, e.g., mRNA, this capacity needs to be built, and this typically takes time.
... this can be relatively easily achieved, because existing infrastructure can be used (Table 1) . For vaccines based on novel technologies, e.g., mRNA, this capacity needs to be built, and this typically takes time. Although it would be beneficial if even a limited number of doses were available to ...
Ref: SARS-CoV-2 Vaccines: Status Report [Immunity, 2020-04-06]This review aims at highlighting the present stages of development of vaccines and discussing the challenges that may be faced with these novel vaccines.
... by the beginning of 2021. There are more than 164 candidate vaccines which are in the process of development and among them 24 vaccines are in advanced stages of development. This review aims at highlighting the present stages of development of vaccines and discussing the challenges that may be faced with these novel vaccines. ...
Ref: Vaccine Against Covid-19 Disease - Present Status of Development [Indian J Pediatr, 2020]The most difficult scientific challenge for this future vaccine obtained in the laboratory is the proof of clinical safety and efficacy.
... new technological platforms and advanced genetic engineering procedures are required to obtain a COVID19 vaccine. The most difficult scientific challenge for this future vaccine obtained in the laboratory is the proof of clinical safety and efficacy. The biggest challenge of manufacturing is the construction and validation of production platforms capable of ...
Ref: Towards effective COVID19 vaccines: Updates, perspectives and challenges (Review) [Int J Mol Med, 2020]Such an approach is in the interests of public health, scientifically responsible, and realizes key ethics values.
... weeks and months ahead, African sites should be central to COVID-19 vaccine trial site mapping. Such an approach is in the interests of public health, scientifically responsible, and realizes key ethics values. Without such an approach, Africa risks being left behind in our response to the COVID-19 ...
Ref: The Case for Why Africa Should Host COVID-19 Candidate Vaccine Trials [J Infect Dis, 2020-06-03]The Ad5 vectored COVID-19 vaccine was immunogenic, inducing humoral and T-cell responses rapidly in most participants.
... The Ad5 vectored COVID-19 vaccine was immunogenic, inducing humoral and T-cell responses rapidly in most participants. Onset of detectable immune responses was rapid, with T-cell responses peaking at day 14 after vaccination and antibodies peaking at day 28. The antibody response to the vaccine in the ...
Ref: Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial [Lancet, 2020-05-22]For each study, the main intervention characteristics, the design used, and the local or global center partnerships created are highlighted.
... clinical trial databases, this systematic review summarizes the global race for vaccine development against COVID-19. For each study, the main intervention characteristics, the design used, and the local or global center partnerships created are highlighted. Most vaccine developments have taken place in Asia, using a viral vector method. Two purified ...
Ref: Current Clinical Trials Protocols and the Global Effort for Immunization against SARS-CoV-2. [Vaccines, 2020-08-25]Atomic-level structures directed the application of prefusion-stabilizing mutations that improved expression and immunogenicity of betacoronavirus spike proteins.
... A SARS-CoV-2 vaccine is needed to control the global COVID-19 public health crisis. Atomic-level structures directed the application of prefusion-stabilizing mutations that improved expression and immunogenicity of betacoronavirus spike proteins. Using this established immunogen design, the release of SARS-CoV-2 sequences triggered immediate rapid manufacturing of an mRNA ...
Ref: SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness [bioRxiv, 2020-06-11]For vaccines based on novel technologies, e.g., mRNA, reaching this capacity typically takes time.
... attenuated vaccines, this can be relatively easy to achieve, because existing infrastructure can be used. For vaccines based on novel technologies, e.g., mRNA, reaching this capacity typically takes time. Although it would be advantageous even if a restricted number of doses were available to ...
Ref: Overview of the current promising approaches for the development of an effective severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine [Int Immunopharmacol, 2020-08-24]Needle-free mucosal vaccination by the intranasal or pulmonary route offers advantages for COVID-19 protection as well as for mass immunization.
... of product distribution and route of administration should be considered at this stage as well. Needle-free mucosal vaccination by the intranasal or pulmonary route offers advantages for COVID-19 protection as well as for mass immunization. Formulating vaccines into dry powder can help improve the thermostability of the vaccines and ultimately ...
Ref: The COVID-19 Vaccine Race: Challenges and Opportunities in Vaccine Formulation [AAPS PharmSciTech, 2020-08-05]A vaccine must stimulate effective antibody and T cell responses in vivo to induce long-term protection.
... 2 (SARS-CoV-2), a novel coronavirus, is essential for stopping the current coronavirus disease (COVID-19) pandemic. A vaccine must stimulate effective antibody and T cell responses in vivo to induce long-term protection. Scientific researchers have been developing vaccine candidates for the severe acute respiratory syndrome (SARS) and ...
Ref: SARS-CoV-2 vaccine research and development: conventional vaccines and biomimetic nanotechnology strategies [AAPS PharmSciTech, 2020]Many different technologies are being used in an effort to prevent the infection or at least the disease.
... Over 100 attempts are being made to develop a vaccine for use in the epidemic of COVID-19. Many different technologies are being used in an effort to prevent the infection or at least the disease. ...
Ref: Vaccination Against Severe Acute Respiratory Syndrome Coronavirus 2 [J Pediatric Infect Dis Soc, 2020-08-03]The designed vaccine was antigenic, immunogenic, and non-allergenic with suitable physicochemical properties and has higher solubility.
... of the three epitope classes such as cytotoxic T-lymphocytes, helper T-lymphocyte, and linear B-lymphocyte epitopes. The designed vaccine was antigenic, immunogenic, and non-allergenic with suitable physicochemical properties and has higher solubility. More importantly, the predicted vaccine structure was similar to the native protein. Further investigations indicated ...
Ref: Designing a multi-epitope vaccine against SARS-CoV-2: an immunoinformatics approach [J Biomol Struct Dyn, 2020]The inactivated NDV-S vaccine was immunogenic, inducing strong binding and/or neutralizing antibodies in both animal models.
... membrane-anchored form of the spike (NDV-S) as a potent COVID-19 vaccine in mice and hamsters. The inactivated NDV-S vaccine was immunogenic, inducing strong binding and/or neutralizing antibodies in both animal models. More importantly, the inactivated NDV-S vaccine protected animals from SARS-CoV-2 infections or significantly attenuated SARS-CoV-2 ...
Ref: A Newcastle disease virus (NDV) expressing membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine [bioRxiv, 2020-07-31]Novel administration technologies might also include microneedle array patches, reconstitution administration devices, and jet injectors.
... It will be challenging to rapidly mobilize a large experienced vaccinator workforce during a pandemic. Novel administration technologies might also include microneedle array patches, reconstitution administration devices, and jet injectors. Not requiring a needle and syringe could make it easier for non-technical persons to be ...
Ref: Anticipating SARS-CoV-2 Vaccine Testing, Licensure, and Recommendations for Use [J Pediatr, 2020-06-19]Development has been expediated by using existing technological platforms and by performing preclinical and clinical testing simultaneously.
... years to develop a vaccine, it has only taken just over 9 weeks from the publication of the viral genetic sequence for the first vaccine candidate to reach clinical testing. Development has been expediated by using existing technological platforms and by performing preclinical and clinical testing simultaneously. ...
Ref: [At least 68 vaccine candidates under development]. [Lakartidningen, 2020-04-06]mRNA-based vaccines are a promising new platform that is highly versatile, safe, effective, simplified, scalable and cheap,
... mRNA-based vaccines are a promising new platform that is highly versatile, safe, effective, simplified, scalable and cheap, has the potential to be free of cold chains [67, 69, 70] . Importantly, mRNA-based vaccines can meet the requirement for rapid and large amounts of effective vaccines against emerging ...
Ref: SARS-CoV-2 vaccine research and development: conventional vaccines and biomimetic nanotechnology strategies [Asian J Pharm Sci, 2020-09-01]To mitigate the effects of the virus on public health, the economy and society, a vaccine is urgently needed.
... 2019 in China and is the causative agent of the coronavirus disease 2019 (COVID-19) pandemic. To mitigate the effects of the virus on public health, the economy and society, a vaccine is urgently needed. Here I review the development of vaccines against SARS-CoV-2. Development was initiated when the genetic ...
Ref: SARS-CoV-2 vaccines in development [Nature (Lond.), 2020]The aim is to increase knowledge of possible viral detection methods, which highlights several new technology limitations and advantages.
... control measures. Lay Summary: An innovative analysis is evaluating the nature of the COVID-19 pandemic. The aim is to increase knowledge of possible viral detection methods, which highlights several new technology limitations and advantages. We have assessed some drugs currently for patients (Lopinavir, Ritonavir, Anakinra and Interferon beta 1a), ...
Ref: COVID-19: Underpinning Research for Detection, Therapeutics, and Vaccines Development [Pharm Nanotechnol, 2020]We seek to provide a balanced coverage of the seven main platforms used in vaccine development
... trials and describe a number of the early candidates that are emerging in the field. We seek to provide a balanced coverage of the seven main platforms used in vaccine development that will lead to a desired target product profile for the “ideal” vaccine. Using tales ...
Ref: A Snapshot of the Global Race for Vaccines Targeting SARS-CoV-2 and the COVID-19 Pandemic [Front. Pharmacol., 2020]investigational therapies, sponsorship, critical design elements, and specified outcomes.
... to describe the characteristics of the currently registered clinical trials related to COVID-19, such as investigational therapies, sponsorship, critical design elements, and specified outcomes. Our analysis could provide timely important information of COVID-19 clinical trials from ChiCTR for clinicians, ...
Ref: Profiles of COVID-19 clinical trials in the Chinese Clinical Trial Registry [Emerging microbes & infections, 2020-07-22]Vaccines are a powerful measure to protect the health of individuals and to combat outbreaks such as the COVID-19 pandemic.
... Vaccines are a powerful measure to protect the health of individuals and to combat outbreaks such as the COVID-19 pandemic. An ethical dilemma arises when one effective vaccine has been successfully developed against an epidemic disease and researchers seek to test the efficacy of another vaccine for the same pathogen ...
Ref: cord_uid fzbu506l Ethical considerations for epidemic vaccine tr... fzbu506l Ethical considerations for epidemic vaccine tr... Name: title, dtype: object [Emerging microbes & infections, cord_uid fzbu506l 2020 fzbu506l 2020 Name: publish_time, dtype: object]mRNA-1273 Modified mRNAs are synthetic molecules optimized for high-level and durable protein expression.
... these vaccines have advanced to human trials without data in animals establishing efficacy against COVID-19. mRNA-1273 Modified mRNAs are synthetic molecules optimized for high-level and durable protein expression. This technology has shown promise as a vaccine platform for influenza virus (NCT03076385 and NCT03345043) ...
Ref: The Challenges of Vaccine Development against a New Virus during a Pandemic [Cell Host Microbe, 2020-05-13]live attenuated virus, viral vectors, inactivated virus, subunit vaccines, recombinant DNA, and protein vaccines.
... to prevent SARS-CoV-2 infection (14) . There are different vaccine development platforms against SARS-CoV-2, including live attenuated virus, viral vectors, inactivated virus, subunit vaccines, recombinant DNA, and protein vaccines. Several studies are in progress, but requires months to years to develop the vaccines for ...
Ref: A review on Promising vaccine development progress for COVID-19 disease [Vacunas, 2020-06-13]Live attenuated vaccines (LAV) are viruses that are rendered replication-incompetent through repeated passage in cell culture,
... Live attenuated vaccines (LAV) are viruses that are rendered replication-incompetent through repeated passage in cell culture, and inactivated vaccines utilise whole pathogen which has typically been killed by exposure to chemicals (e.g. formaldehyde) or heat inactivation (33) . LAV are immunogenic and reproduce the breadth of ...
Ref: The early landscape of COVID‐19 vaccine development in the UK and rest of the world [Immunology, 2020-05-27]The direct COVID-19 impact upon children is greater than that observed for a number of other pathogens for which we now have effective pediatric vaccines.
... into Phase 3 clinical trials, clinical trials have not started in children in the US. The direct COVID-19 impact upon children is greater than that observed for a number of other pathogens for which we now have effective pediatric vaccines. Additionally, the role of children in SARS-CoV-2 transmission has clearly been underappreciated. Carefully conducted Phase ...
Ref: Warp Speed for COVID-19 Vaccines: Why are Children Stuck in Neutral? [Immunology, 2020]highly flexible, scalable, inexpensive and cold-chain-free.
... clinical trials of mRNA vaccines for infectious disease are still in their early stage, a plethora of publications have shown that mRNAbased vaccines are a promising novel platform that is highly flexible, scalable, inexpensive and cold-chain-free. ...
Ref: mRNA Vaccines: Possible Tools to Combat SARS-CoV-2 [Virol Sin, 2020-06-10]Several subunit vaccines, peptides, nucleic acids, plant-derived, recombinant vaccines are under pipeline.
... SARS-CoV-2 vaccine started based on the full-length genome analysis of severe acute respiratory syndrome coronavirus. Several subunit vaccines, peptides, nucleic acids, plant-derived, recombinant vaccines are under pipeline. This article concludes and highlights ongoing advances in drug repurposing, therapeutics and vaccines to counter ...
Ref: An evidence-based systematic review on emerging therapeutic and preventive strategies to treat novel coronavirus (SARS-CoV-2) during an outbreak scenario. [Journal of basic and clinical physiology and pharmacology, 2020-09-14]Dendritic cells loaded with immunodominant epitopes are a vaccine platform shown to exclusively activate CD8+ T cells without inciting an innate immune response.
... especially a CD8+ cytotoxic T cell response, has come from SARS-CoV vaccination studies in mice. Dendritic cells loaded with immunodominant epitopes are a vaccine platform shown to exclusively activate CD8+ T cells without inciting an innate immune response. When loaded with SARS-CoV epitopes, this vaccine has been shown to protect BALB/c and B6 ...
Ref: Principles Learned from the International Race to Develop a Safe and Effective COVID-19 Vaccine [ACS Cent Sci, 2020-07-21]Certain vaccine formulations have induced sub-optimal Abs and inappropriate Th2-mediated immune responses,
... First, safety issues must be initially evaluated. Certain vaccine formulations have induced sub-optimal Abs and inappropriate Th2-mediated immune responses, leading to Ab dependent enhancement (ADE) and/or vaccine-associated enhanced respiratory disease (VAERD) (99, [179] [180] [181] [182] [183] . Additionally, each candidate should ...
Ref: Newly Emerging Human Coronaviruses: Animal Models and Vaccine Research for SARS, MERS, and COVID-19 [Immune Netw, 2020-07-22]The speed of scientific discovery related to COVID-19 is unprecedented.
... develop and test novel vaccines to protect against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The speed of scientific discovery related to COVID-19 is unprecedented. With several vaccine candidates already being tested in clinical trials, we pose the question: what ...
Ref: The VACCINES Act: Deciphering Vaccine Hesitancy in the Time of COVID-19 [Clin Infect Dis, 2020]properly adjuvanted recombinant protein or DNA/mRNA encoding an engineered sequence of trimeric S protein in pre-fusion conformation.
... the experience of developing Middle East respiratory syndrome coronavirus (MERS-CoV) and SARS-CoV vaccine candidates in preclinical and clinical trials, the most promising strategies for SARS-CoV-2 vaccines should employ viral-vector platforms, properly adjuvanted recombinant protein or DNA/mRNA encoding an engineered sequence of trimeric S protein in pre-fusion conformation. ...
Ref: Perspectives on development of vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). [Human vaccines & immunotherapeutics, 2020-09-22]the genome structure and phylogenetic analysis of the virus, methods of .
... Knowing the various characteristic of the SARS-COV-2 virus and the disease COVID-19 caused by it, the genome structure and phylogenetic analysis of the virus, methods of . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has ...
Ref: Mapping the Global Research and Clinical Trials in COVID-19 [Human vaccines & immunotherapeutics, 2020-06-29]HCTs could help evaluate vaccine efficacy, identify correlates of protection, and understand pathogenesis and the immune response.
In the context of the COVID-19 pandemic, HCTs could help evaluate vaccine efficacy, identify correlates of protection, and understand pathogenesis and the immune response.
Ref: Evaluating use cases for human challenge trials in accelerating SARS-CoV-2 vaccine development [Clin Infect Dis, 2020-07-06]Chemical and physical methods such as formaldehyde, UV light or β-propiolactone are being deployed for the preparation of inactivated virus vaccine.
... lymphocyte (CTL) epitopes in the SARS-CoV-2 spike protein. Different vaccine vectors are also being developed. Chemical and physical methods such as formaldehyde, UV light or β-propiolactone are being deployed for the preparation of inactivated virus vaccine. Currently, there are many vaccines undergoing clinical trials. Even though mRNA and DNA vaccines are ...
Ref: Coronavirus Disease (COVID-19): Current Status and Prospects for Drug and Vaccine Development. [Archives of medical research, 2020-09-10]RNA and DNA vaccines are two new vaccine technologies currently in focus for COVID-19 vaccine development.
... live virus. Meanwhile recombinant protein-based and vector-based vaccines are safe but require epitope selection, antigen design, and vehicle development. Some new-generation vaccine types were not produced on large scale before. RNA and DNA vaccines are two new vaccine technologies currently in focus for COVID-19 vaccine development. ...
Ref: Frontiers in the COVID-19 vaccines development [Exp Hematol Oncol, 2020-09-03]It is influenced by factors such as complacency, convenience and confidence [9] .
... vaccination services. Vaccine hesitancy is complex and context specific, varying across time, place and vaccines. It is influenced by factors such as complacency, convenience and confidence [9] . We evaluated participants" self-reported vaccine hesitancy according to the WHO definition using three previously adapted ...
Ref: Intention to participate in a COVID-19 vaccine clinical trial and to get vaccinated against COVID-19 in France during the pandemic [Vaccine, 2020-09-17]Chemical and physical methods such as formaldehyde, UV light or ß-propiolactone are being deployed for the preparation of inactivated virus vaccine.
... lymphocyte (CTL) epitopes in the SARS-CoV-2 spike protein. Different vaccine vectors are also being developed. Chemical and physical methods such as formaldehyde, UV light or ß-propiolactone are being deployed for the preparation of inactivated virus vaccine. Currently, there are many vaccines undergoing clinical trials. Even though mRNA and DNA vaccines are ...
Ref: Coronavirus Disease (COVID-19): Current Status and Prospects for Drug and Vaccine Development [Vaccine, 2020]defining detailed targets of humoral and cellular immune responses at the epitope level,
... on understanding the genetic drivers of infection and vaccineinduced humoral and cellular immunity to SARS-CoV-2, defining detailed targets of humoral and cellular immune responses at the epitope level, characterising the B-cell receptor and T-cell receptor repertoire elicited by infection or vaccination, and establishing ...
Ref: SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates [Lancet, 2020-10-13]we have presented a synergistic computational platform, including molecular dynamics simulations and immunoinformatics techniques,
... is yet to be a proven effective treatment or cure for COVID-19 In this study, we have presented a synergistic computational platform, including molecular dynamics simulations and immunoinformatics techniques, to rationally design a multi-epitope vaccine candidate for COVID-19 This platform combines epitopes across Linear ...
Ref: A Rational Design of a Multi-Epitope Vaccine Against SARS-CoV-2 Which Accounts for the Glycan Shield of the Spike Glycoprotein [Lancet, 2020]rapid development, selfadjuvant properties and no cold storage requirement (75).
... that the ADDomer© VLP platform has many of the main benefits of VLP-based vaccines, including rapid development, selfadjuvant properties and no cold storage requirement (75). An ADDomer© VLP vaccine expressing Chikungunya E2 protein also proved immunogenic in pre-clinical trials (76) ...
Ref: The early landscape of COVID‐19 vaccine development in the UK and rest of the world [Immunology, 2020-05-27]These vaccines must provide high efficacy, safety, and tolerability.
... is required to develop a vaccine production platform, providing the scalability, technological flexibility, and versatility. These vaccines must provide high efficacy, safety, and tolerability. This is due to the time required to prove that the proposed vaccine is safe ...
Ref: Towards effective COVID-19 vaccines: Updates, perspectives and challenges (Review) [Int J Mol Med, 2020-05-06]An effective vaccine should be able to induce high titers of neutralizing antibodies to prevent the virus from attaching to the host cell receptors.
... a suitable vaccine against COVID-19 (Coronavirus Disease-19) caused by SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus-2). An effective vaccine should be able to induce high titers of neutralizing antibodies to prevent the virus from attaching to the host cell receptors. However, to elicit the protective levels of antibodies, a vaccine may require multiple doses or ...
Ref: Potential adjuvants for the development of a SARS-CoV-2 vaccine based on experimental results from similar coronaviruses [Int Immunopharmacol, 2020]The vaccine candidates encompass a large diversity of vaccine platforms including mRNA, DNA, nanoparticle, subunit, and viral vectors 8 .
... to elicit polyclonal antibody responses against the spike protein of SARS-CoV-2 to neutralize viral infection. The vaccine candidates encompass a large diversity of vaccine platforms including mRNA, DNA, nanoparticle, subunit, and viral vectors 8 . Some of the new technological platforms, such as DNA and mRNA vaccines, can theoretically enable ...
Ref: Impact of immune enhancement on Covid-19 polyclonal hyperimmune globulin therapy and vaccine development [EBioMedicine, 2020-04-16]Oral and nasal mucosal surfaces serve as the primary portal of entry for pathogens like coronaviruses in the human body.
... an effective therapeutic agent or vaccine for COVID-19 (coronavirus disease 2019) are being undertaken globally. Oral and nasal mucosal surfaces serve as the primary portal of entry for pathogens like coronaviruses in the human body. As evidenced by studies on similar coronaviruses (SARS-CoV and MERS-CoV), mucosal vaccination can provide a ...
Ref: Prospects for mucosal vaccine: shutting the door on SARS-CoV-2 [Human vaccines & immunotherapeutics, 2020-09-15]It is highly desirable that a potential vaccine will induce a potent antibody response as well as long-term .
... It is highly desirable that a potential vaccine will induce a potent antibody response as well as long-term . Identifying the epitopes that are targeted by these antibodies will be crucial to determine the antigenic sites on the spike of SARS-CoV-2. Although traditionally an effective vaccine should mainly aim ...
Ref: COVID‐19 vaccines: knowing the unknown [Eur J Immunol, 2020-05-21]their degree of protection and the pathophysiological mechanism of the disease were analyzed in this review article.
... and pathophysiology of disease. The types of biotechnological candidate vaccines to be developed against COVID-19, their degree of protection and the pathophysiological mechanism of the disease were analyzed in this review article. The literature data on which cruxes for the development of biotechnological candidate vaccines to be ...
Ref: How close are we to a COVID-19 vaccine? [J. Pure Appl. Microbiol., 2020]providing the scalability, technological flexibility, and versatility.
... a high variability of the virus, it is required to develop a vaccine production platform, providing the scalability, technological flexibility, and versatility. These vaccines must provide high efficacy, safety, and tolerability. This is due to the time ...
Ref: Towards effective COVID-19 vaccines: Updates, perspectives and challenges (Review) [Int J Mol Med, 2020-05-06]The isolation and properties of neutralizing monoclonal antibodies from COVID-19 patients provide additional information on what vaccines should try to elicit.
... that is triggered by SARS-CoV-2 infection of humans, and how it may inform vaccine research. The isolation and properties of neutralizing monoclonal antibodies from COVID-19 patients provide additional information on what vaccines should try to elicit. The nature and longevity of the antibody response to coronaviruses are relevant to the potency ...
Ref: SARS-CoV-2 vaccines: 'Warp Speed' needs mind melds not warped minds [J. virol, 2020]it was extremely useful to support vaccine licensing and market use.
... which reported the main results of pre-license clinical trials and post-marketing evaluation of various vaccines, it was extremely useful to support vaccine licensing and market use. We encourage the continuous clinical studies and post-marketing evaluation of vaccines, including the novel corona ...
Ref: [Conduct vaccines clinical trials and optimize the immunization strategies]. [Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine], 2020-09-06]COVID-19 vaccines will be essential in the future for reducing morbidity and mortality and inducing herd immunity,
... not be timely available to have an impact on the first wave of the ongoing COVID-19 pandemic. Nevertheless, COVID-19 vaccines will be essential in the future for reducing morbidity and mortality and inducing herd immunity, if SARS-CoV-2 becomes established in the population like for example influenza virus. ...
Ref: The Long Road Toward COVID-19 Herd Immunity: Vaccine Platform Technologies and Mass Immunization Strategies [Front Immunol, 2020]it contains the major neutralizing epitopes and is located on the surface of the viral particle.
... The S protein is the major antigen in most COVID-19 vaccine candidates under development as it contains the major neutralizing epitopes and is located on the surface of the viral particle. However, the full-length S protein of SARS-CoV also contains several immunodominant sites that can induce ...
Ref: Learning from the past: development of safe and effective COVID-19 vaccines [Nat Rev Microbiol, 2020-10-16]Immunoinformatic and molecular modelling are time-efficient methods that are generally used to accelerate the discovery and design of the candidate peptides for vaccine development.
... a few repurposed drugs. The urgency of the situation requires the development of SARS-CoV-2-based vaccines. Immunoinformatic and molecular modelling are time-efficient methods that are generally used to accelerate the discovery and design of the candidate peptides for vaccine development. In recent years, the use of multiepitope vaccines has proved to be a promising immunization ...
Ref: A Putative Prophylactic Solution for COVID-19: Development of Novel Multiepitope Vaccine Candidate against SARS-COV-2 by Comprehensive Immunoinformatic and Molecular Modelling Approach. [Biology, 2020-09-18]Among currently registered clinical efforts, ~86% are centered on testing small molecules or antibodies either alone or in combination with immunomodulators.
... and treatment. Presently, a tremendous surge of COVID-19 clinical trials are advancing through different stages. Among currently registered clinical efforts, ~86% are centered on testing small molecules or antibodies either alone or in combination with immunomodulators. The rest ~14% of clinical efforts are aimed at evaluating vaccines and convalescent plasma-based therapies ...
Ref: Emerging Therapeutic Modalities against COVID-19 [Pharmaceuticals (Basel), 2020-08-08]Among all approaches, a messenger RNA (mRNA)-based vaccine has emerged as a rapid and versatile platform to quickly respond to this challenge.
... urgent need for vaccines against coronavirus disease 2019 (COVID-19) because of the ongoing SARS-CoV-2 pandemic. Among all approaches, a messenger RNA (mRNA)-based vaccine has emerged as a rapid and versatile platform to quickly respond to this challenge. Here, we developed a lipid nanoparticle-encapsulated mRNA (mRNA-LNP) encoding the receptor binding domain (RBD) of ...
Ref: A Thermostable mRNA Vaccine against COVID-19 [Cell, 2020]Some platforms offer key advantages such as viral vectors with their strong immune response, superior protein expression, and prolonged stability,
... viruses, replicating and nonreplicating viral vectors, DNA and mRNA, virus-like particles, and recombinant protein-based approaches. Some platforms offer key advantages such as viral vectors with their strong immune response, superior protein expression, and prolonged stability, and DNA or mRNA offers antigen manipulation flexibility, whereas the recombinant protein-based development approach is ...
Ref: Nanotechnology for COVID-19: Therapeutics and Vaccine Research [ACS Nano, 2020-06-22]This mRNA vaccine codes for a prefusion-stabilized form of the S protein [115] .
... line of developing a COVID-19 vaccine, mRNA-1273 that is currently undergoing clinical trials [115] . This mRNA vaccine codes for a prefusion-stabilized form of the S protein [115] . This vaccine somehow resembles gene therapy and when administered, it leads to protein production by ...
Ref: Overview of the current promising approaches for the development of an effective severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine [Int Immunopharmacol, 2020-08-24]The platform technology offers speed and adaptability, so these vaccine candidates can be rapidly developed by repurposing previously developed nanostructures as shown by Moderna.
... testing for the past 30 years, but the technology has not been previously approved. 14 The platform technology offers speed and adaptability, so these vaccine candidates can be rapidly developed by repurposing previously developed nanostructures as shown by Moderna. 15 Likewise, Novavax"s vaccine is also modeled off of their previous vaccine against influenza. 16 ...
Ref: COVID-19 Vaccine Frontrunners and Their Nanotechnology Design [ACS Nano, 2020-10-09]fast vaccine development, a clean safety profile, and low production costs [35] .
... interest. Undoubtedly, at first glance, nucleic acid immunization appears to be an attractive vaccine platform: fast vaccine development, a clean safety profile, and low production costs [35] . However, in spite of the promising data from preclinical animal studies, DNA vaccines have not ...
Ref: Vaccine Development Against Middle East Respiratory Syndrome [Curr Trop Med Rep, 2016-07-11]this information helps in the development of effective and safe vaccines for COVID-19.
... past and ongoing vaccine development efforts for clinically relevant coronavirus strains with the intention that this information helps in the development of effective and safe vaccines for COVID-19. In addition, information from naturally exposed individuals and animal models to coronavirus strains is described ...
Ref: Vaccines for SARS-CoV-2: Lessons from Other Coronavirus Strains [Infect Dis Ther, 2020]COVCCF has ideal pharmacokinetic properties and low immune-related toxicities.
... T-cytotoxic lymphocytes. COVCCF induces cytokines important to innate immunity, including IFN-γ, IL4, and IL10. Additionally, COVCCF has ideal pharmacokinetic properties and low immune-related toxicities. In summary, this study provides a powerful, computational vaccine design platform for rapid development of ...
Ref: A Rational Design of a Multi-Epitope Vaccine Against SARS-CoV-2 Which Accounts for the Glycan Shield of the Spike Glycoprotein. [ChemRxiv : the preprint server for chemistry, 2020-08-07]The COVID-19 vaccine developers need to carefully follow standard developmental and evaluation pathways of safety, immunogenicity, protective immunity, duration of vaccination protection,
The COVID-19 vaccine developers need to carefully follow standard developmental and evaluation pathways of safety, immunogenicity, protective immunity, duration of vaccination protection, easy delivery systems, practical dosing regimens, stability, cold
Ref: Advancing COVID-19 vaccines – avoiding different regulatory standards for different vaccines and need for open and transparent data sharing [Int J Infect Dis, 2020-08-19]There are two nucleic acid platforms: DNA (12 candidates) and RNA (20 + candidates),
... platforms of vaccine development, along with an eighth catch-all "Other" category ( Figure 4 ). There are two nucleic acid platforms: DNA (12 candidates) and RNA (20 + candidates), which could be sub-divided further according to particular traits related to delivery and carriers (e.g. ...
Ref: A Snapshot of the Global Race for Vaccines Targeting SARS-CoV-2 and the COVID-19 Pandemic [Front Pharmacol, 2020-06-19]the World Health Organization has registered 173 vaccine candidates as being in development Six candidates have entered phase 3 trials,
... has therefore been pinned on a vaccine that can protect against the disease COVID-19 As of August 2020, the World Health Organization has registered 173 vaccine candidates as being in development Six candidates have entered phase 3 trials, and the first results from these are expected in the autumn eng ...
Ref: Status of COVID-19 vaccine development [Tidsskr Nor Laegeforen, 2020]The nature and longevity of the antibody response to coronaviruses are relevant to the potency and duration of vaccine-induced immunity.
... monoclonal antibodies from COVID-19 patients provide additional information on what vaccines should try to elicit. The nature and longevity of the antibody response to coronaviruses are relevant to the potency and duration of vaccine-induced immunity. We summarize the immunogenicity of leading vaccine candidates tested to date in animals and humans ...
Ref: cord_uid vd2a6uof COVID-19 Vaccines: "Warp Speed" Needs Mind Mel... vd2a6uof COVID-19 Vaccines: "Warp Speed" Needs Mind Mel... Name: title, dtype: object [Tidsskr Nor Laegeforen, cord_uid vd2a6uof 2020 vd2a6uof 2020 Name: publish_time, dtype: object]An efficacy trial, which measures whether the vaccine reduces the incidence of disease, is ordinarily required to fully evaluate vaccine efficacy.
... the outbreak, the urgency for developing candidate vaccines has brought distinct challenges to clinical development. An efficacy trial, which measures whether the vaccine reduces the incidence of disease, is ordinarily required to fully evaluate vaccine efficacy. However, emergency use may be possible if promising immunogenicity results are observed. A ring vaccination ...
Ref: Considerations on the clinical development of COVID-19 vaccine from trial design perspectives [Hum Vaccin Immunother, 2020]Developing COVID-19 vaccines is a crucial challenge, and several candidates are currently under basic development [3] .
... Respiratory Syndrome and/or Severe Acute Respiratory Syndrome were identified. Since this statement, COVID-19 had emerged. Developing COVID-19 vaccines is a crucial challenge, and several candidates are currently under basic development [3] . Some of them will be tested in Phase I trials in the weeks to come ...
Ref: Intention to participate in a COVID-19 vaccine clinical trial and to get vaccinated against COVID-19 in France during the pandemic [Hum Vaccin Immunother, 2020-04-27]consider what vaccine designs could reduce safety concerns and how animal models and immunological assessments in early clinical trials can help to assess the risk.
... 12 and 13, 2020 of experts in the field of vaccine immunology and coronaviruses to consider what vaccine designs could reduce safety concerns and how animal models and immunological assessments in early clinical trials can help to assess the risk. This report summarizes the evidence presented and provides considerations for safety assessment of COVID-19 vaccine ...
Ref: Consensus summary report for CEPI/BC March 12-13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines [Vaccine, 2020]Vaccines, such as inactivated vaccines, nucleic acid-based vaccines, and vector vaccines, have already entered clinical trials.
... considerable efforts have been put into developing effective and safe drugs and vaccines against SARS-CoV-2. Vaccines, such as inactivated vaccines, nucleic acid-based vaccines, and vector vaccines, have already entered clinical trials. In this review, we provide an overview of the experimental and clinical data obtained from ...
Ref: A systematic review of SARS-CoV-2 vaccine candidates [Signal Transduct Target Ther, 2020]Vaccine hesitancy was associated with a decrease in COVID-19 vaccine acceptance.
... COVID-19, being a healthcare worker and individual perceived risk were associated with COVID-19 vaccine acceptance. Vaccine hesitancy was associated with a decrease in COVID-19 vaccine acceptance. One thousand and five hundred and fifty respondents (47.6% 95% CI 45.9-49.3%) will certainly or ...
Ref: Intention to participate in a COVID-19 vaccine clinical trial and to get vaccinated against COVID-19 in France during the pandemic [Vaccine, 2020]the development and availability of a vaccine candidate is a time-consuming process and often can't be completed during an epidemic Currently,
... is key to the effort to provide preventive measures against COVID-19 and future viruses However, the development and availability of a vaccine candidate is a time-consuming process and often can"t be completed during an epidemic Currently, several types of vaccines are under development, and most of them won"t realistically be available ...
Ref: COVID-19: Prospective Challenges and Potential Vaccines [Alternative therapies in health and medicine, 2020]The ultimate goal of an ideal COVID-19 vaccine is to generate long-term T and B cell memory.
... against SARS-CoV-2 infection. Further studies are ongoing to explore utilizing this vaccine construct in oral, intranasal, and sublingual formulations to induce mucosal immunity in addition to cell-mediated and humoral immunity. The ultimate goal of an ideal COVID-19 vaccine is to generate long-term T and B cell memory. ...
Ref: A Next Generation Bivalent Human Ad5 COVID-19 Vaccine Delivering Both Spike and Nucleocapsid Antigens Elicits Th1 Dominant CD4+, CD8+ T-cell and Neutralizing Antibody Responses [bioRxiv, 2020-07-30]MSCs may reduce the pathological changes that occur in the lungs and inhibit the cell-mediated inflammatory response.
... various diseases. MSCs are being investigated in a clinical trial for COVID-19, which focuses on the safety and efficiency of MSC therapy for pneumonia patients infected with SARS-CoV-2 [37] . MSCs may reduce the pathological changes that occur in the lungs and inhibit the cell-mediated inflammatory response. ...
Ref: COVID-19: An Update Regarding the Quest for Finding an Effective Cure [Cureus, 2020-07-05]provided in-depth insight into the various types of vaccines, their compositions, advantages, and potential limitations.
... this review, we described the COVID-19 vaccines that are currently tested in clinical trials and provided in-depth insight into the various types of vaccines, their compositions, advantages, and potential limitations. We also addressed how challenges in vaccine distribution and administration may be alleviated by applying ...
Ref: The COVID-19 Vaccine Race: Challenges and Opportunities in Vaccine Formulation [AAPS PharmSciTech, 2020]